Publications & Patents

Publications & Patents

Total 72건 1 페이지
Publications & Patents 목록
No. 제목
72
Publication

Cancers (Basel).

2023

Abstract(1) Background: This study investigated whether polo-like kinase 4 (PLK4) is a suitable therapeutic target or biomarker for lung adenocarcinoma (LUAD). (2) Methods: We acquired LUAD data from The Cancer Genome Atlas (TCGA) database through the UCS…

21시간 전 3
71
Publication

Front Bioeng Biotechnol.

2023

AbstractThe incidence and mortality rates of lung cancer are high worldwide, where non-small cell lung cancer (NSCLC) accounts for more than 85% of lung cancer cases. Recent non-small cell lung cancer research has been focused on analyzing patient prognosis af…

21시간 전 3
70
Publication

Clin Transl Immunology.

2022

AbstractObjectives: AXL-mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti-tumor and anti-metastatic activities of SKI-G-801, a small-molecule inh…

21시간 전 2
69
Publication

Yonsei Med J.

2022

AbstractPurpose: Agonists of the stimulator of interferon genes (STING) play a key role in activating the STING pathway by promoting the production of cytokines. In this study, we investigated the antitumor effects and activation of the systemic immune re…

21시간 전 3
68
Publication

Front Oncol.

2023

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease controlPDF 파일 참고 부탁드립니다.

21시간 전 3
67
Publication

Ther Adv Med Oncol.

2022

AbstractIntroduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR-mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in…

22시간 전 3
66
Publication

Front Oncol.

2022

AbstractA recently developed treatment strategy for lung cancer that combines immune checkpoint inhibitors with chemotherapy has been applied as a standard treatment for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), and it has improved th…

22시간 전 2
65
Publication

Front Chem.

2022

AbstractAmong cancer cells, indoleamine 2, 3-dioxygenase1 (IDO1) activity has been implicated in improving the proliferation and growth of cancer cells and suppressing immune cell activity. IDO1 is also responsible for the catabolism of tryptophan to kynurenin…

5일 전 29
64
Publication

Cancer Treat Rev.

2021

AbstractThe development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are an…

5일 전 27
63
Publication

Cancers (Basel).

2021

AbstractCancer cells are able to reprogram their glucose metabolism and retain energy via glycolysis even under aerobic conditions. They activate the hexosamine biosynthetic pathway (HBP), and the complex interplay of O-linked N-acetylglucosaminylation (O-GlcN…

5일 전 25
62
Publication

Eur J Cancer.

2021

AbstractBackground: The predictive value of immune monitoring with circulating CD8+ T lymphocytes for treatment response to programmed cell death protein 1 (PD-1) inhibitors has not been explored in non-small-cell lung cancer (NSCLC), prompting us to…

5일 전 24
61
Publication

Eur J Cancer.

2021

AbstractObjective: Anti-programmed death (PD)-1 therapy confers sustainable clinical benefits for patients with non-small-cell lung cancer (NSCLC), but only some patients respond to the treatment. Various clinical characteristics, including the PD-ligand …

5일 전 22
60
Publication

Cancers (Basel).

2021

AbstractUp to 40% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) may develop central nervous system (CNS) metastases throughout their disease. Moreover, the first- and second-generation EGFR-tyrosi…

5일 전 22
59
Publication

Cancer Discovery

2020

AbstractEGFR exon 20 insertion driver mutations (Exon20ins) in non-small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR-MET, has shown preclinical activit…

5일 전 22
58
Publication

J Immunother Cancer.

2020

AbstractBackground: EML4-ALK is a distinct molecular entity that is highly sensitive to ALK tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors (ICIs) have not proved efficacy in ALK-positive non-small cell lung cancer so far. In thi…

5일 전 22

검색